---
authors:
- Ebell, Mark
category: Clinical Review
clinical_significance: High
external_resources:
- title: PubMed Entry
  type: reference
  url: https://pubmed.ncbi.nlm.nih.gov/38215431/
file_path: 2023/12/terbinafine-250-mg-once-daily-12-weeks-on-12-weeks-off-four.md
issue: '6'
keywords:
- Antifungal Agents
- Terbinafine
- Humans
- Adult
- Treatment Outcome
- Onychomycosis
- Foot Dermatoses
last_updated: '2025-07-30'
mesh_terms:
- Adult
- Humans
- Terbinafine
- Onychomycosis
- Antifungal Agents
- Treatment Outcome
- Foot Dermatoses
original_format: PubMed
pages: Online
patient_population: Adults
peer_reviewed: true
pmid: '38215431'
processed_date: '2025-07-30'
publication_date: '2023-12-01'
pubmed_enriched: true
pubmed_enriched_date: '2025-07-30'
reading_time_minutes: 5
source: American family physician
specialty:
- Family Medicine
status: processed
tags:
- clinical-review
- family-practice
- clinical-medicine
- pubmed-enhanced
title: Terbinafine, 250 mg Once Daily-12 Weeks on, 12 Weeks off, Four Weeks on-Is Preferred for Onychomycosis in Adults.
topics:
- Family Medicine
volume: '108'
---

# Terbinafine, 250 mg Once Daily-12 Weeks on, 12 Weeks off, Four Weeks on-Is Preferred for Onychomycosis in Adults.

**Authors:** Ebell, Mark

**Published in:** American family physician | Vol. 108, No. 6 | 2023-12-01

**Links:** [PubMed](https://pubmed.ncbi.nlm.nih.gov/38215431/)

## Clinical Information

**Population:** Adults | **Clinical Significance:** High

## Topics & Specialties

**Specialties:** Family Medicine

**Topics:** Family Medicine

## MeSH Terms

Adult, Humans, Terbinafine, Onychomycosis, Antifungal Agents, Treatment Outcome, Foot Dermatoses

## Article Content

*Full article content to be extracted and formatted from source material.*

## Additional Resources

- [PubMed Entry](https://pubmed.ncbi.nlm.nih.gov/38215431/) (reference)

---

*Processed: 2025-07-30* | *PubMed Enhanced: 2025-07-30*
